Cladribine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2902 publications

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics

Published: June 24, 2026

Differences in the imaging of Erdheim-Chester disease using FDG-PET/CT, NaF-PET/CT examinations, and skeletal scintigraphy. Regression of the disease after treatment with cladribine combined with cyclophosphamide and anakinra.

Differences in the imaging of Erdheim-Chester disease using FDG-PET/CT, NaF-PET/CT examinations, and skeletal scintigraphy. Regression of the disease after treatment with cladribine combined with cyclophosphamide and anakinra.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: June 22, 2026

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Journal: Leukemia & lymphoma

Published: June 12, 2026

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Journal: Neurology and therapy

Published: June 01, 2026

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

Journal: American journal of hematology

Published: May 20, 2026

Cladribine treatment of a young patient with isolated progressive pulmonary Langerhans histiocytosis complicated by invasive aspergillosis.

Cladribine treatment of a young patient with isolated progressive pulmonary Langerhans histiocytosis complicated by invasive aspergillosis.

Journal: Polish archives of internal medicine

Published: May 08, 2026

Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.

Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 26, 2026

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 16, 2026

Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis.

Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: April 07, 2026

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Journal: Neurodegenerative disease management

Published: April 07, 2026

The use of cladribine tablets in patients with MS beyond the age of 50: experiences from a large tertiary German centre.

The use of cladribine tablets in patients with MS beyond the age of 50: experiences from a large tertiary German centre.

Journal: Neurological research and practice

Published: April 01, 2026

Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS.

Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS.

Journal: Transplantation and cellular therapy

Published: March 26, 2026

Showing 1-12 of 2,902

Last Updated: 06/30/2026